Project Grant R01AR083900
Award Date
6/12/24
Completion Date
5/31/29
Dollars Obligated
$652K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis (OA) development. The 5-year project, running from August 1, 2024 to July 31, 2029, aims to evaluate the potential of NFAT1 as a therapeutic target...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,476,001.00 to The Regents of the University of California, San Francisco to conduct research on the systemic origins of osteoarthritis (OA). The research aims to define how adipose (fat) tissue communicates with joint tissues to drive OA pathology, exploring three potential mechanisms: signaling through secreted factors, cell...
This $571,650 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research program) supports research to repurpose FDA-approved drugs for the treatment of osteoarthritis. The project aims to use high-throughput screening in innovative human cell-derived microphysiological models to identify and evaluate potential disease-modifying osteoarthritis drugs (DMOADs). Key aspects...
This $644,887 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to elucidate the role of the WNT16 signaling pathway in regulating chondrocyte (cartilage cell) biology and its potential to mitigate the development of hip osteoarthritis (OA). The research aims to determine the genetic and epigenetic mechanisms by which...
This $624,004.07 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), to Thomas Jefferson University's Sidney Kimmel Medical College. The award will fund research to investigate the role of hypoxia-inducible factor-1 (HIF-1) in regulating glucose metabolism and lactate/pyruvate dynamics in intervertebral disc cells, with the goal of...
This federal Project Grant award of $2,029,684 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to develop a novel in vitro "miniature joint" (MiniJoint) model for investigating the role of adipose tissue and its impacts on osteoarthritis (OA). The key objectives are to: 1) define the influence of normal adipose tissue on OA pathogenesis in the...
This $219,605 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research to investigate the role of the mechanosensitive ion channel PIEZO1 in driving synovial fibrosis and inflammation in post-traumatic osteoarthritis (PTOA). The research, led by Easton Farrell (PhD student) and sponsored by Tristan Maerz, PhD and Kurt Hankenson, DVM, PhD,...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $393,412 Project Grant under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research) to Vanderbilt University. The grant, which runs from September 17, 2024 to July 31, 2029, supports research to develop engineered cell therapies as agents for arthritis treatment. Key objectives include characterizing synthetic receptors to drive cartilage repair in an in vitro arthropathy model (Aim 1),...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to establish a new "microphysiological joint-on-chip" system for the study of arthritic diseases and rapid testing of treatment candidates. The $618,629 award, effective from August 15, 2024 to July 31, 2029, will fund the development of human-derived biomaterial inks and...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $426,889 project grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Southern California (USC) to investigate the molecular regulatory mechanisms of a cartilage-enriched G-protein coupled receptor (GPCR) named ADGRG6 in maintaining joint homeostasis and preventing osteoarthritis (OA). The project aims to elucidate the role of ADGRG6 signaling in...